About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a new study.
..
.
Reasons for ibrutinib therapy discontinuation in CLL
About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a new study.
There are currently 1 users browsing this thread. (0 members and 1 guests)
Posting Permissions
Quote